Meiji Yasuda Life Insurance Co Buys Shares of 8,555 Solventum Corporation $SOLV

Meiji Yasuda Life Insurance Co purchased a new position in shares of Solventum Corporation (NYSE:SOLV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,555 shares of the company’s stock, valued at approximately $625,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new stake in Solventum in the 2nd quarter valued at about $28,000. Deseret Mutual Benefit Administrators raised its position in Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares during the period. MUFG Securities EMEA plc purchased a new stake in Solventum in the second quarter valued at approximately $31,000. State of Wyoming acquired a new position in Solventum during the second quarter worth $33,000. Finally, MTM Investment Management LLC purchased a new position in shares of Solventum during the second quarter worth $40,000.

Solventum Trading Down 2.1%

Shares of NYSE:SOLV opened at $69.30 on Monday. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $88.20. The company’s 50 day moving average is $77.62 and its two-hundred day moving average is $76.20. The company has a market cap of $12.02 billion, a PE ratio of 7.81, a P/E/G ratio of 1.14 and a beta of 0.40. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter in the previous year, the firm posted $1.41 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a stock repurchase program on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Finally, KeyCorp boosted their price target on shares of Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Solventum presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.70.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.